Comparing intermittent and continuous PD-1 inhibitor therapy for metastatic melanoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to compare the effectiveness of intermittent versus continuous administration of PD-1 inhibitors in patients with unresectable or metastatic melanoma. Researchers will evaluate whether both treatment schedules yield similar outcomes in terms of patient survival. The study involves administering a government-approved PD-1 inhibitor either continuously or with breaks, depending on the patient's response. The goal is to determine if an intermittent approach could provide similar benefits while potentially reducing side effects and healthcare costs.

Why it matters

Who can join: the full rules

Minimum age 18 or as specified in the Product Monograph and eligible for public funding.

Inclusion Criteria:

* Histologically confirmed melanoma that is unresectable / metastatic (stage III or stage IV).
* Eligible to receive treatment with a government approved and publically-funded PD-1 inhibitor, according to the guidance / indications described in the Product Monograph / Provincial Formulary.
* Patients must have evidence of unresectable / metastatic disease, that is considered evaluable by the investigator and can be followed, but measurable disease is not mandatory.
* Patients with brain metastases are allowed, provided they are stable according to the following definitions:

  1. Without evidence of progression for at least four weeks prior to randomization and have no evidence of new or enlarging brain metastases.
  2. Treated with surgery and without evidence of progression prior to randomization and have no evidence of new or enlarging brain metastases.
  3. Treated with stereotactic radiosurgery and without evidence of progression prior to randomization and have no evidence of new or enlarging brain metastases.
* Patient is able (i.e. sufficiently fluent) and willing to complete the quality of life and health utility questionnaires in either English or French. The baseline assessment must be completed within required timelines, prior to randomization. Inability (lack of comprehension in English or French, or other equivalent reason such as cognitive issues or lack of competency) to complete the questionnaires will not make the patient ineligible for the study. However, ability but unwillingness to complete the questionnaires will make the patient ineligible.
* Patient consent must be appropriately obtained in accordance with applicable local and regulatory requirements. Each patient must sign a consent form prior to enrollment in the trial to document their willingness to participate.
* Patients must be accessible for treatment and follow-up. Investigators must assure themselves the patients randomized on this trial will be available for complete documentation of the treatment, adverse events, and follow-up.
* Patients must be randomized prior to the start of, or within 16 weeks from, the initiation of PD-1 inhibitor treatment. For patients who are being randomized before the start of treatment, the PD-1 inhibitor should be started within 5 working days after randomization. Patients who initiate treatment with combination anti-PD-1 and anti-CTLA-4 therapies who experience toxicity may be randomized at the time prior to starting single-agent PD-1 inhibitor. Repeat imaging must be done within 50 days prior to randomization to ensure the patient has no evidence of disease progression

Exclusion Criteria:

* Patients not willing to stop anti-PD-1 therapy, if randomized to the intermittent arm.
* Patients with any contraindications to PD-1 inhibitors, as described in the Product Monograph or Provincial Formulary, and/or not eligible to receive anti-PD-1 therapy.

Where it's running

• Mildura Base Public Hospital
  Victoria, Mildura, Australia Recruiting
• Coffs Habour Health Campus - NCCI
  Coffs Harbour, New South Wales, Australia Recruiting
• Calvary Mater Newcastle Hospital
  Waratah, New South Wales, Australia Recruiting
• Westmead Hospital
  Westmead, New South Wales, Australia Recruiting
• Sunshine Coast University Hospital
  Birtinya, Queensland, Australia Recruiting
• Cairns Hospital
  Cairns, Queensland, Australia Recruiting

Study contacts

• Study coordinator: Janet Dancey
• Email: jdancey@ctg.queensu.ca
• Phone: 613-533-6430

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Asking people in CCTG cancer trials about social, economic, and environmental factors

  This project asks adults in Canadian Cancer Trials Group (CCTG) cancer trials to fill a short questionnaire to see if patients are willing to share social, economic, and environmental information that affects health.

  Recruiting at 15 sites Canadian Cancer Trials Group · Calgary, Alberta and 14 other locations · NCT07390435

• Sonrotoclax and Zanubrutinib With CAR-T in Mantle Cell Lymphoma

  This trial tests whether adding two oral drugs, sonrotoclax and zanubrutinib, to standard CAR-T therapy helps people with mantle cell lymphoma who have relapsed or are refractory after prior treatment.

  Recruiting at 5 sites Phase 2 Canadian Cancer Trials Group · Calgary, Alberta and 4 other locations · NCT07341191

• GCAR1 CAR-T therapy for GPNMB-expressing solid tumours

  This study tests different doses of GCAR1 CAR-T cells in people with specific cancers that make high levels of the GPNMB protein to see if the treatment is safe and how it affects the cancer.

  Recruiting at 3 sites Phase 1 Canadian Cancer Trials Group · Calgary, Alberta and 3 other locations · NCT07297667

• Durvalumab + Tremelimumab with or without Lenvatinib for unresectable liver cancer

  This trial tests whether adding lenvatinib to the STRIDE regimen (durvalumab plus tremelimumab) helps people with unresectable hepatocellular carcinoma who have not received prior systemic therapy.

  Recruiting at 13 sites Phase 2 Canadian Cancer Trials Group · Calgary, Alberta and 12 other locations · NCT06880523

• Targeted radiotherapy to control limited progression in metastatic non-small cell lung cancer

  This study will try adding focused high-dose radiotherapy (SBRT) to standard immunotherapy or chemo-immunotherapy for people with metastatic non-small cell lung cancer who have a few sites starting to grow (oligoprogression).

  Recruiting at 75 sites Phase 3 Canadian Cancer Trials Group · Phoenix, Arizona and 74 other locations · NCT06686771

• Comparing two types of radiation therapy for advanced head and neck cancer

  This study tests if a new type of radiation therapy called SBRT can help people with advanced head and neck cancer better than the standard radiation treatment.

  Recruiting at 10 sites Phase 3 Canadian Cancer Trials Group · Calgary, Alberta and 9 other locations · NCT06641791

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.